Production & Sales

Regeneron forms consortium to accelerate sequencing of UK Biobank data

A new partnership between Regeneron Pharmaceuticals and five other drug manufacturers intends to accelerate the generation of genetic exome sequence data from the 500,000 participants of the UK Biobank.

Cardiff University researchers develop new tool to assess racemisation risk in drugs

Researchers at Cardiff University in the UK have developed a new method to test the likelihood of a drug turning into a potentially harmful version of itself when it enters the body.

ANI Pharmaceuticals buys four AstraZeneca NDAs

ANI Pharmaceuticals has acquired the new drug applications (NDAs) and US marketing rights for AstraZeneca’s Atacand, Atacand HCT, Arimidex, and Casodex for $46.5m.

Mallinckrodt to acquire Sucampo Pharmaceuticals for $1.2bn

Mallinckrodt has signed a deal to acquire US-based Sucampo Pharmaceuticals for about $1.2bn to add the latter’s constipation medication Amitiza (lubiprostone) and other commercial and development assets to its portfolio.

Drugmaker Teva to cut 14,000 jobs globally

Teva Pharmaceutical Industries said it will lay off 14,000 jobs globally as part of a two-year restructuring plan, aimed at boosting its business and financial performance.

Flexion Therapeutics to acquire novel and non-opioid asset for osteoarthritis of knee

Flexion Therapeutics has entered into a definitive agreement with GeneQuine Biotherapeutics GmbH to acquire the global rights to GQ-203.

Ardelyx signs license agreement with Fosun Pharma for tenapanor in China

Ardelyx has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company (Fosun Pharma) for tenapanor.

Arena, Everest Medicines partner for Ralinepag and Etrasimod in China

Arena Pharmaceuticals and Everest Medicines have entered into a development and commercialization partnership for ralinepag and etrasimod in mainland China, Taiwan, Hong Kong, Macau, and South Korea (the "Territories").

Melinta Therapeutics to buy The Medicines Company’s infectious disease business

Melinta Therapeutics has agreed to acquire the infectious disease business from The Medicines Company.